These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 3252203)

  • 21. [Nifedipine in the treatment of hypertrophic non-obstructive cardiomyopathy].
    Senn M; Hess OM; Krayenbühl HP
    Schweiz Med Wochenschr; 1982 Sep; 112(38):1312-7. PubMed ID: 6215710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypertrophic occlusive cardiomyopathy.
    Kaltenbach M; Hopf R
    Clin Invest Med; 1980; 3(1-2):179-84. PubMed ID: 7008998
    [No Abstract]   [Full Text] [Related]  

  • 23. Verapamil in the treatment of hypertrophic cardiomyopathy.
    Rosing DR; Epstein SE
    Ann Intern Med; 1982 May; 96(5):670-2. PubMed ID: 6122414
    [No Abstract]   [Full Text] [Related]  

  • 24. [Clinical and hemodynamic effects of verapamil in hypertrophic obstructive cardiomyopathy].
    Lösse B; Kuhn H; Loogen F
    Z Kardiol; 1982 Dec; 71(12):813-9. PubMed ID: 6891873
    [No Abstract]   [Full Text] [Related]  

  • 25. [Echocardiographic parameters in hypertrophic cardiomyopathy during verapamil treatment (author's transl].
    Lemke R; Hopf R; Kober G; Kaltenbach M
    Z Kardiol; 1980 Oct; 69(10):661-8. PubMed ID: 7192909
    [No Abstract]   [Full Text] [Related]  

  • 26. Calcium antagonists for hypertrophic cardiomyopathy.
    Vaisrub S
    JAMA; 1980 Apr; 243(14):1464. PubMed ID: 7188980
    [No Abstract]   [Full Text] [Related]  

  • 27. [Effect of verapamil on the indicators of left-ventricular diastole in hypertrophic cardiomyopathy].
    Dabrowski M; Górecka B; Witkowski A; Jodkowski J; Woroszylska M; Ruzyłło W
    Kardiol Pol; 1986; 29(5-6):345-55. PubMed ID: 3784250
    [No Abstract]   [Full Text] [Related]  

  • 28. [Beta adrenergic receptors in patients with untreated and verapamil-treated hypertrophic cardiomyopathy].
    Kölbel F; Krulík R; Slíva D; Hradec J; Aschermann M; Simper D; Schreiber V
    Sb Lek; 1988 Jul; 90(7):218-22. PubMed ID: 2851875
    [No Abstract]   [Full Text] [Related]  

  • 29. [Calcium antagonists. Concept and therapeutic applications].
    Eichelbaum M
    Med Welt; 1982 Aug; 33(31-32):1079-82. PubMed ID: 6890137
    [No Abstract]   [Full Text] [Related]  

  • 30. [The use of the delayed-action form of korinfar in arterial hypertension, stenocardia and hypertrophic cardiomyopathy].
    Barats SS; Smolenskaia OG; Klets FKh; Zubareva TV; Zakroeva AG; Kots IaI; Tenchurina LR
    Ter Arkh; 1996; 68(1):39-42. PubMed ID: 8644029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Left ventricular relaxation in hypertrophic cardiomyopathy and possibilities of controlling it with verapamil].
    Gregor P; Widimský P; Cervenka V; Vísek V; Sládková T; Dvorák J
    Cas Lek Cesk; 1987 Mar; 126(11):330-4. PubMed ID: 3829106
    [No Abstract]   [Full Text] [Related]  

  • 32. [Long-term treatment of hypertrophic non obstructive cardiomyopathy (HNCM) with verapamil (author's transl)].
    Kuhn H; Thelen U; Leuner C; Köhler E; Bluschke V
    Z Kardiol; 1980 Oct; 69(10):669-75. PubMed ID: 7192910
    [No Abstract]   [Full Text] [Related]  

  • 33. [Personal experience with the long-term administration of verapamil in hypertrophic cardiomyopathies].
    Gregor P; Widimský P; Cervenka V; Vísek V; Dvorák J; Sládková T
    Vnitr Lek; 1986 Dec; 32(12):1179-87. PubMed ID: 3824917
    [No Abstract]   [Full Text] [Related]  

  • 34. [Does verapamil affect the thickness of the cardiac muscle in hypertrophic cardiomyopathy?].
    Gregor P; Widimský P; Cervenka V; Vísek V; Sládková T; Dvorák J
    Vnitr Lek; 1986 Dec; 32(12):1188-96. PubMed ID: 3824918
    [No Abstract]   [Full Text] [Related]  

  • 35. [Hemodynamic effect of verapamil and nifedipine in chronic heart failure].
    Merzon KA; Doviner AD; Zolotov NA; Kolomiets VV; Kiriaev AA
    Klin Med (Mosk); 1986 Apr; 64(4):45-9. PubMed ID: 3724012
    [No Abstract]   [Full Text] [Related]  

  • 36. [Reduction of coronary artery cross section during conservative therapy of hypertrophic obstructive cardiomyopathy].
    Kaltenbach M; Hopf R; Petersen Y; Kober G
    Verh Dtsch Ges Kreislaufforsch; 1977; 43():358-9. PubMed ID: 565994
    [No Abstract]   [Full Text] [Related]  

  • 37. [Do guide lines for differential therapy in hypertrophic obstructive cardiomyopathy exits?].
    Kaltenbach M; Hopf R; Bussmann WD; Kober G; Petersen Y; Keller M
    Cardiology; 1978; 63 Suppl 1():77-9. PubMed ID: 28845
    [No Abstract]   [Full Text] [Related]  

  • 38. [Importance of current ultrasonic study methods for the diagnosis, follow-up of treatment effectiveness and prognosis of patients with hypertrophic obstructive cardiomyopathy].
    Pal L; Fedorova IF; Schäfer R; Sergakova LM; Naumov VG
    Ter Arkh; 1987; 59(10):90-4. PubMed ID: 3433228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hypertrophic cardiomyopathy: place and limitations of medical therapy].
    Desnos M; Hagège A; Guérot C
    Arch Mal Coeur Vaiss; 1995 Apr; 88(4 Suppl):573-5. PubMed ID: 7487302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Common with the uncommon--atrial septal defect with hypertrophic cardiomyopathy.
    Matta R; Nair SK; Balakrishnan KG
    Indian Heart J; 1995; 47(4):372-4. PubMed ID: 8557282
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.